COUNTY OF SAN LUIS OBISPO HEALTH AGENCY
PUBLIC HEALTH DEPARTMENT
Michael Hill *Health Agency Director*
Penny Borenstein, MD, MPH *Health Officer/Public Health Director*

PROVIDER HEALTH ADVISORY

Date: February 25, 2022
Contact: Rick Rosen, MPH, MD, 805-781-5500, frosen@co.slo.ca.us

COVID-19 Update: Second Dose of Evusheld for Immunocompromised Patients

Dosing Update

The FDA recently announced a modification to the Emergency Use Authorization for AstraZeneca's COVID-19 therapeutic Evusheld.

Evusheld now should be administered as an initial dose of 600mg. **Individuals who already received the previously authorized initial 300mg dose should receive a second Evusheld dose as soon as possible.**

Recommendations will be made in the near future when more data are available to determine the appropriate timing of redosing (e.g., a repeat dose with 150mg of tixagevimab and 150mg of cilgavimab at 3 months or 6 months after the initial dose).

The updated EUA can be found here: www.fda.gov/media/154704/download

###

About Evusheld

Evusheld is a combination of two monoclonal antibodies (tixagevimab and cilgavimab) that is indicated for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2, and
- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination, or
- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s). Due to limited supplies of Evusheld, the NIH COVID-19 Treatment Guidelines Panel recommended that priority for use as pre-exposure prophylaxis should be given to those who are at the highest risk for severe COVID-19.

It should be noted that patients at high risk who have mild to moderate COVID-19 can be treated with authorized and approved therapeutic products to help prevent progression to severe disease. For more detail on who qualifies as high risk, see recommendations from the NIH COVID-19 Treatment Guidelines Panel at:
www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management

For More Information

For more information about COVID-19 therapeutics and treatments, visit
www.slopublichealth.org/treatments